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AMPA receptors respond to the neurotransmitter glutamate and play a critical role in excitatory
neurotransmission. They have been implicated in several psychiatric disorders and have rich
pharmacology. Antagonists of AMPA receptors have been explored as drugs and one has even reached
the clinic. We now introduce a freely diffusible photoswitchable antagonist that is selective for AMPA
receptors and endows them with light-sensitivity. Our photoswitch, ShuBQX-3, is active in its dark-
adapted trans-isoform but is significantly less active as its cis-isoform. ShuBQX-3 exhibits a remarkable
red-shifting of its photoswitching properties through interactions with the AMPA receptor ligand binding
site. Since it can be used to control action potential firing with light, it could emerge as a powerful tool
for studying synaptic transmission with high spatial and temporal precision.Introduction
Photopharmacology is the attempt to endow biological targets
with light sensitivity using small photoswitchable molecules.1 It
has been applied to a wide variety of molecular targets,
including ion channels,2 G-protein coupled receptors (GPCRs)3
and enzymes.4 As such, it has enabled the light-dependent
control of diverse cellular processes, such as proliferation5 and
neuronal excitability.6
The ionotropic glutamate receptors (iGluRs) are attractive
targets for photopharmacology due to their fundamental roles
in excitatory neurotransmission7 and their involvement in
neurodegenerative conditions and psychiatric disorders.8 The
iGluRs are natively gated by the neurotransmitter glutamate
and are divided into three subclasses due to their individual
responses to selective agonists: AMPA receptors (GluAs), kainate
receptors (GluKs) and NMDA receptors (GluNs).9
To date, all three of the iGluR subtypes have been addressed
with photopharmacology, using freely diffusible photo-
switchable agonists.10 Although synthetic agonists for neuro-
transmitter receptors are powerful tools, they do create a non-
physiological situation that can complicate the analyses ofor Integrated Protein Science, Ludwig
tstraße 5-13, 81377 Munich, Germany.
Biochemistry, Ruhr-Universität-Bochum,
ESI) available: Experimental procedures
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Chemistry 2016neural networks. This is perhaps the reason why antagonists of
glutamatergic signaling are more widely used in neuroscience
and why they have undergone extensive development as drugs
to treat psychiatric diseases.11 It would be advantageous to use
light to precisely control glutamate receptor antagonists and
target their actions to specic locations. To that end, a few
caged antagonists of iGluRs have been disclosed12 but their
activation is irreversible. This prompted us to develop a photo-
switchable antagonist that can be reversibly turned on and off.
Our studies resulted in a quinoxaline-2,3-dione derivative,
termed ShuBQX-3,§ that enables the optical control of AMPA
receptor-mediated action potential ring of hippocampal
neurons.Results and discussion
Our design of ShuBQX-3 was based on the vast array of antag-
onists for AMPA receptors that have been developed.13 These
encompass compounds that exhibit non-competitive antago-
nism, such as perampanel,14 which is clinically used, as well as
those that compete for the glutamate binding site. Competitive
AMPA receptor antagonists that contain the quinoxaline-2,3-
dione motif (Fig. 1a and b), are an extremely well developed
family of antagonists and have undergone extensive structure–
activity relationship (SAR) studies.15
Starting from the parent compound DNQX, a wide array of
more selective and more soluble derivatives have been devel-
oped, including CNQX and NBQX (Fig. 1a). To increase solu-
bility, carboxylate or phosphonate moieties were introduced on
the nitrogen in position 4, which gave rise to zonampanel,
LU115455 and MPQX (fanampanel) (Fig. 1b).14Chem. Sci.
Fig. 1 (a) Molecular structures of quinoxaline-2,3-dione AMPA
receptor antagonists. (b) Molecular structures of quinoxaline-2,3-
dione AMPA receptor antagonists with increased solubility. (c)
Molecular structures of the designed photochromic AMPA receptor
antagonists ShuBQX-1, ShuBQX-2 and ShuBQX-3.
Scheme 1 Synthesis of the photochromic AMPA receptor antagonists
ShuBQX-1 and ShuBQX-2.
Scheme 2 Synthesis of the photochromic AMPA receptor antagonist
ShuBQX-3.























































































View Article OnlineWe postulated that an azobenzene moiety could be accom-
modated in the 6-position of the quinoxaline-2,3-dione core as
sterically bulky substituents are tolerated in this position. Our
design hypothesis was also supported by a X-ray crystal struc-
ture of the compound MPQX bound to a GluA2 receptor.16 The
crystal structure strongly suggested that a reasonable amount of
steric bulk could be accommodated in the 6-position of the
quinoxaline-2,3-dione without interfering with the binding of
the antagonist. On the other hand, we concluded that photo-
isomerization of such a moiety would change the affinity of
a ligand bound to the clamshell-like ligand binding domain. At
the very least, this could be mediated by a reorganization of the
solvation sphere upon photoisomerization. We also added the
phosphonic acid side chain from the antagonist MPQX as it
dramatically improves the solubility of the compound in
aqueous solutions.17 When considering all of our strategic
aspects, the photoswitchable antagonists ShuBQX-1, ShuBQX-2
and ShuBQX-3 were designed (Fig. 1c).
We then set about preparing our target photoswitches,
initially focusing on ShuBQX-1 and ShuBQX-2 (Scheme 1).
Starting from dichloride 1 and aminomethylphosphonic acid (2)
a SNAr reaction furnished phosphonic acid 3, which was pro-
tected to afford phosphonate ester 4. Suzuki coupling reactions
using boronic acids 5 and 6, bearing Boc-protected anilines in
the meta- and para-positions, respectively, were performed to
provide biaryls 7 and 8. Subsequent reduction of the nitro group
followed by cyclization with ethyl chlorooxoacetate (11) afforded
the desired meta- and para-amino substituted quinoxaline-2,3-
diones 12 and 13. Quinoxaline 12 was then converted to meta-
azobenzene 15 in an azo-coupling reaction with N,N-dimethyla-
niline (14) and ShuBQX-1was furnished aer deprotection of the
phosphonate ester using 6 M HCl followed by reverse phase
chromatography. The preparation of ShuBQX-2 followed the
same azo-coupling and deprotection procedures as ShuBQX-1,Chem. Sci.with moderate yields of the desired products being obtained in
both reactions.
We next accomplished the synthesis of ShuBQX-3 starting
from phosphonate ester 4 (Scheme 2). A Buchwald–Hartwig
cross-coupling of N-Boc protected hydrazine 17 with phospho-
nate ester 4 afforded protected hydrazine 18 in 72% yield.
Reduction of the nitro group followed by cyclization to the
quinoxaline-2,3-dione using ethyl chlorooxoacetate (11) and
subsequent deprotection of the phosphonate ester gave
ShuBQX-3 in 18% yield (over three steps).
With our small family of soluble, photochromic ligands in
hand, we rst deduced the optimum photoswitching wave-
lengths using UV-Vis spectroscopy (Fig. S1†) and then deter-
mined their functional properties as light-controllable AMPA
receptor antagonists. Whole-cell patch-clamp electrophysiology
of HEK293T cells expressing GluA1-L497Y receptors (a non-
desensitizing AMPA receptor mutant)18 found that the photo-
chromic ligands ShuBQX-1 (5 mM) and ShuBQX-2 (5 mM) are
good antagonists of AMPA receptors in the presence of gluta-
mate (300 mM). However, upon photoisomerization using blue
(460 nm) and green (560 nm) light only a small change in AMPA
receptor antagonism was observed (Fig. 2a). We then evaluated
ShuBQX-3 (5 mM) and discovered that it is an excellent photo-
switchable antagonist of AMPA receptors.This journal is © The Royal Society of Chemistry 2016
Fig. 2 Whole-cell patch-clamp characterization of ShuBQX-1,
ShuBQX-2 and ShuBQX-3 in the presence of glutamate (300 mM)
using HEK293T cells transfected with GluA1-L497Y receptors. (a)
Comparison of relative photocurrent of ShuBQX-1, ShuBQX-2 and
ShuBQX-3 (5 mM). Values represent mean  SEM. (b) Action spectrum
of ShuBQX-3 (20 mM) under illumination with orange light (600 nm)
and varying wavelengths (400–500 nm). (c) Photoswitching of
ShuBQX-3 (10 mM) using 460 nm and 600 nm light over multiple
switching cycles. Traces representative of n ¼ 5 cells.
Fig. 3 Selectivity profile of ShuBQX-3 (5 mM) in the dark at various
glutamate receptors expressed in Xenopus oocytes. Currents were
induced using the following methods: GluA1-containing receptors ¼
kainic acid (100 mM); GluK2 – containing receptors ¼ glutamate
(100 mM, left column) and glutamate (30 mM, right column); GluN1-1a-
containing receptors¼ glutamate (100 mM) and glycine (10 mM). Values
represent mean  SEM (n ¼ 5 oocytes).























































































View Article OnlineFirst, we determined the IC50 value of ShuBQX-3 in the
absence of light and in the presence of glutamate (300 mM). It
was found to be 3.1 mM (Fig. S3†). A very similar value (IC50 ¼
3.3 mM) was obtained when illuminating ShuBQX-3 with orange
light (600 nm). At this wavelength, the photoswitch largely
resides in the trans-form. Under blue light illumination
(460 nm), which favors the cis-state of ShuBQX-3, the antagonist
was signicantly less potent than in the dark-adapted state
(Fig. 2). Finally, experiments conducted using ShuBQX-3 with
differing concentrations of glutamate (100 mM and 1 mM)
conrmed that it is a competitive antagonist of GluA1 receptors
(Fig. S4†). Further studies on the biological activity of ShuBQX-3
using patch-clamp electrophysiology showed that glutamate-
induced currents are completely blocked in its trans-form. Upon
illumination with 460 nm light, 50% of the glutamate-induced
current (compared to the current induced in the absence of
ShuBQX-3) could be released (Fig. 2a). We then determined the
action spectrum of ShuBQX-3 in the presence of glutamate.
When the wavelength was switched between orange light
(600 nm) and different wavelengths of purple blue and green
light (400–500 nm), we observed large differences in current
(Fig. 2b). The maximum inward current was consistently
observed when illuminating with 440 nm or 460 nm (Fig. S5†)
whereas minimum inward currents were observed using long
wavelength light or in the dark. Reversible photoactivation of
AMPA receptors with ShuBQX-3 is robust and could be repeated
over many times without any signicant loss of receptor
antagonism (Fig. 2c). Highly reproducible photoswitching of
ShuBQX-3 was also obtained when operating in current-clamp
mode (Fig. S6†).This journal is © The Royal Society of Chemistry 2016To determine the selectivity prole of ShuBQX-3 (5 mM) in its
dark state, we evaluated its effects on Xenopus oocytes express-
ing a variety of glutamate receptors (Fig. 3). ShuBQX-3 (5 mM)
showed excellent antagonism of all GluA1-containing receptors
that were tested (85–93%). By contrast, the amount of antago-
nism observed at this concentration on the GluK2 receptor was
signicantly reduced (25%) when inducing the current using
glutamate (100 mM). Reducing the concentration of glutamate
(30 mM) increased the amount of antagonism exhibited by
ShuBQX-3 at the GluK2 receptor (49%). Thus, indicating that
the dark state of ShuBQX-3 is a competitive antagonist of the
GluK2 receptor. Additionally, ShuBQX-3 (5 mM) was evaluated
against several GluN1-1a-containing receptors. ShuBQX-3
(5 mM) displayed minimal antagonism at the GluN1-1a-con-
taining glutamate receptors, demonstrating that ShuBQX-3 is
partially selective for AMPA receptors over kainate, whilst
having signicantly reduced levels of antagonism at NMDA
receptors.
With the full evaluation of ShuBQX-3 in transfected
HEK293T cells and Xenopus oocytes complete, we set out to
demonstrate that ShuBQX-3 could control native AMPA recep-
tors in excitable cells. For these experiments we used acute
mouse brain slice preparations and whole cell patch-clamp
electrophysiology of hippocampal CA1 neurons. Pleasingly,
when ShuBQX-3 (10 mM) and glutamate (100 mM) were locally
applied in a brain slice preparation, the induced action poten-
tial ring of a single neuron could be effectively controlled by
switching between blue (460 nm) and orange (620 nm) light
(Fig. 4). The NMDA-receptor antagonist AP-5 (50 mM) was locally
added to ensure that the action potential ring was not caused
by any interactions between the NMDA receptors and gluta-
mate. Additionally, we were able to optically control hippo-
campal CA1 neurons when using AMPA as the agonist (Fig. S7†).
Demonstrating that ShuBQX-3 is selective for AMPA receptors.
The action spectrum of ShuBQX-3 is noteworthy, as we
observed a signicant difference between the optimalChem. Sci.
Fig. 4 Optical control of action potential firing in hippocampal CA1
neurons using ShuBQX-3 (10 mM) in the presence of glutamate
(100 mM) and AP-5 (50 mM).























































































View Article Onlinephotoswitching wavelengths established by the UV-Vis experi-
ments and the physiological patch-clamp experiments. In our
UV-Vis experiments, a solution of ShuBQX-3 (50 mM in DMSO)
displayed optimal photoswitching at 380 nm (trans to cis) and
460 nm (cis to trans), with a lmax ¼ 365 nm for the trans-isomer
(Fig. 5a, S1†). However, in the patch-clamp experiments in
HEK293T cells expressing the GluA1 receptor, ShuBQX-3
exhibited a bathochromic shi in its action spectrum, with
optimal photoswitching now taking place when illuminating
with 460 nm and 600 nm light.19 In an attempt to ascertain why
this bathochromic shi was occurring, we consulted the X-ray
crystal structure of the non-photoswitchable antagonist MPQX
bound to a GluA2 receptor (Fig. 5c).16 The structure features
prominent interaction between the guanidinium moiety of
arginine R-485, which is also involved in glutamate binding,
and the quinoxaline-2,3-dione core of MPQX. We therefore
postulated that this interaction could have an effect on the
photoswitching properties of ShuBQX-3 when it is bound to the
GluA1 receptor.Fig. 5 UV-Vis analysis of the photoswitching properties of ShuBQX-3.
(a) UV-Vis spectrum showing ShuBQX-3 (50 mM in DMSO) and the
bathochromic shift in the presence of 1 mM L-arginine. (b) UV-Vis
spectrum ShuBQX-3 (50 mM) in DMSO in the presence of 1 mM
L-arginine when illuminated with 460 nm and 600 nm light. (c) X-ray
structure of MPQX bound to a GluA2 receptor ligand binding domain,
showing the interaction between a conserved arginine and the qui-
noxaline-2,3-dione.16
Chem. Sci.To probe this possible interaction, we took the UV-Vis solu-
tion of ShuBQX-3 (50 mM in DMSO) and doped it with L-argi-
nine. Indeed, a bathochromic shi of 75 nm (lmax ¼ 440 nm) in
the UV-Vis spectrum of ShuBQX-3 was observed (Fig. 5a) with
a 20-fold excess of L-arginine. The optimum photoswitching
wavelengths of ShuBQX-3 were now demonstrated to be 460 nm
and 600 nm (Fig. 5b). When L-arginine was replaced by guani-
dine, a similar bathochromic shi was observed (Fig. S8†),
substantiating our hypothesis. UV-Vis experiments conducted
with the diethyl phosphonate of ShuBQX-3 showed that the
phosphonic acid side chain is not crucial for the interaction
(Fig. S9†). We also measured the thermal relaxation rate of
ShuBQX-3 in the presence of L-arginine (s ¼ 1.68 min) and
found it to be faster than the rate of ShuBQX-3 alone (s ¼
7.37 min). This is in accordance to the rate acceleration of red-
shied azobenzenes in comparison to their non red-shied
analogues.20 To the best of our knowledge, this is the rst
example of an azobenzene-based photoswitch to exhibit such
red-shiing properties. Control experiments using ShuBQX-3
(50 mM) dissolved in Ringer's solution showed almost no change
in the absorption maximum (Fig. S1†). Our ndings suggest
that the interaction between R-485 and the quinoxaline-2,3-
dione is responsible for the bathochromic shi in the action
spectrum of ShuBQX-3.
Conclusions
In summary, we have developed a photochromic antagonist that
permits the precise optical control of AMPA receptors. Our
photoswitch, ShuBQX-3, is active as its trans-isomer and is
converted to its cis-isomer using blue light illumination enabled
by red-shiing upon binding to AMPA receptors. ShuBQX-3
expands the photopharmacology of iGluRs and demonstrates
that potent photoswitchable antagonists for these receptors can
be developed. We envision that ShuBQX-3 will be an important
tool for studying the function of AMPA receptors in vivo.
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M. M. Kohl, A. Rodŕıguez-Moreno, O. Paulsen and
H. L. Anderson, Commun. Integr. Biol., 2012, 5, 240–242; (c)
J. J. Chambers, H. Gouda, D. M. Young, I. D. Kuntz and
P. M. England, J. Am. Chem. Soc., 2004, 126, 13886–13887.
13 (a) S. S. Nikam and B. E. Kornberg, Curr. Med. Chem., 2001, 8,
155–170; (b) P. Stawski, H. Janovjak and D. Trauner, Bioorg.
Med. Chem., 2010, 18, 7759–7772.
14 S. Hibi, K. Ueno, S. Nagato, K. Kawano, K. Ito, Y. Norimine,
O. Takenaka, T. Hanada and M. Yonaga, J. Med. Chem., 2012,
55, 10584–10600.
15 D. Catarzi, V. Colotta and F. Varano,Med. Res. Rev., 2007, 27,
239–278.
16 A. I. Sobolevsky, M. P. Rosconi and E. Gouaux, Nature, 2009,
462, 745–756.
17 L. Turski, A. Huth, M. Sheardown, F. McDonald, R. Neuhaus,
H. H. Schneider, U. Dirnagl, F. Wiegand, P. Jacobsen and
E. Ottow, Proc. Natl. Acad. Sci. U. S. A., 1998, 95, 10960–10965.
18 Y. Stern-Bach, S. Russo, M. Neuman and C. Rosenmund,
Neuron, 1998, 21, 907–918.
19 We also conducted patch-clamp experiments in which
ShuBQX-1 and ShuBQX-2 were irradiated with varying
wavelengths of light but no bathochromic shi was
observed for either of these compounds (Fig. S2†).
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